• Activity Title

    Start Activity

    Optimizing Success in Positive Airway Pressure (PAP) Therapy for Obstructive Sleep Apnea: The Role of the Mask

     

  • Statement of Need/Program Overview

    In this educational activity, we will review the importance of the CPAP interface in achieving success in obstructive sleep apnea treatment. We will discuss the evolution of mask technology and mask fitting approaches, including virtual apps. Side effects and outcomes will be compared between nasal and oronasal masks. Evaluation of nasal symptoms, indications for clinical and surgical treatment for nasal obstruction and outcomes of nasal surgency on CPAP use will be discussed. The excessive use of oronasal masks and rationale for choosing nasal masks as first-line options for CPAP treatment will be presented. The mechanisms involved in the better outcomes of nasal masks and of potential ineffectiveness of oronasal CPAP treatment will be reviewed. Detection and management strategies of excessive mouth leak during nasal CPAP will be proposed. 

  • Target Audience

    This activity is intended for healthcare professionals involved in the management of obstructive sleep apnea that include Pulmonologists, Pneumologists, Respirologists, Respiratory Physiotherapists, Respiratory Therapists (Hospital, Home), Neurologists, Pediatricians,  Otorhinolaryngologists, Sleep Technicians,  Home Healthcare Providers, Critical Care Medicine Specialists, Internal Medicine Specialists, Primary Care Physicians (General and Family Practitioners), Advanced Practice Nurses, Nurse Practitioners, Physicians Assistants, Managed Care Medical Directors, and other Practitioners and Payers.

  • Educational Objectives

    After completing this activity, the participant should be better able to:
    1.    Discuss the evolution of mask technology and fitting.
    2.    Compare side effects of nasal and oronasal masks for CPAP treatment.
    3.    Define importance of a patent nasal airway.
    4.    Analyze clinical and surgical intervention outcomes on PAP acceptance & adherence.
    5.    Summarize potential ineffectiveness of oronasal CPAP for OSA patients.
    6.    Describe longitudinal treatment of OSA with nasal CPAP as first line option, including management of excessive oral leak.

  • Faculty

    Pedro Genta, MD
    Associate Professor of Medicine
    Division of Pulmonary Medicine
    University of São Paulo

    Jennifer Newitt, MD
    Assistant Professor of Medicine
    University of Pittsburgh

    Olivier M. Vanderveken, MD, PhD
    Full Professor in Otorhinolaryngology, Head and Neck Surgery & Sleep Surgery
    Translational Neurosciences 
    Vice-Dean 
    Faculty of Medicine and Health Sciences
    University of Antwerp
    Head of Department and Chair
    Department of ENT, Head and Neck Surgery
    Antwerp University Hospital 
    Antwerp, BELGIUM

  • Program Agenda

    Section 1: Overview of PAP masks, approach to fit and impact on PAP therapy adherence (38.5 minutes)
    Section 2: Patient Interface: PAP Therapy for Obstructive Sleep Apnea (28.75 minutes) 
    Section 3: Nasal Masks as first line options for CPAP (39 minutes)

  • Provider Accreditation Statement

    This activity is provided by Global Education Group (Global).

  • Joint Accreditation Statement

    In support of improving patient care, Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

  • Physician Credit Designation

    Global Education Group designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Nurse Practitioner Continuing Education

    AANP Logo

    Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.75 contact hour(s) (which includes 0.0 hour(s) of pharmacology). 

  • Nurse Contact Hours Designation

    Global Education Group designates this continuing education activity for 1.75 contact hours including 0.0 pharmacotherapeutic contact hours.

  • Review Date

    The content for this activity was reviewed on 8/13/2026.

  • Term Offering – Physicians, Nurse Practitioners and Nurses

    This activity was released on August 25, 2026 and is valid for one year. Requests for credit must be made no later than August 25, 2027.

  • Global Contact Information

    For information about the Joint Accreditation (ANCC, AMA PRA Category 1 credit) or approval (AANP) of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

  • Credit Designation - AARC

    This Non-traditional program has been approved for 1.75 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care; 9425 N. MacArthur Boulevard, Suite 100, Irving TX 75063

  • Term Offering - AARC / CRCE

    This activity was released on August 25, 2026. Requests for credit must be made no later than August 25, 2027.

  • Instructions to Receive Credit

    In order to receive credit, participants must complete all of the course lessons. Participants must also score at least a 70% on the posttest. Upon completion of lessons and quizzes, you must also complete the evaluation form. Your certificate will be available to download upon completion of the evaluation.

  • Fee Information

    There is no fee for this educational activity.

  • Disclosure of Relevant Financial Relationships

    Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months.  All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.

  • The following faculty have the relevant financial relationships with ineligible companies:

    Name of Faculty or Presenter Reported Financial Relationship
    Pedro Genta, MD
    Contracted Research: Biologix, Fisher & Paykel Healthcare, ResMed Foundation
    Jennifer L. Newitt, MD Nothing to Disclose
    Oliver Vanderveken, MD, PhD Consulting Fee (e.g., Advisory Board): Inspire Medical Systems
    Contracted Research (Principal Investigators must provide information, even if received by the institution): Inspire Medical Systems, Nyxoah, ProSomnus, Somnomed

     

  • The following planners and managers have no relevant financial relationships with ineligible companies:

    Name of Planner or Manager

    Name of Planner of Manager

    Rhys Williams, MSN, FNP-C, RN (Nurse Planner)

    Andrea Funk

    Kristin Delisi, NP (NP Planner)

    Ashley Cann

    Conor Hughes

    Lauren Sinclair

    Amanda Glazar

    Deborah Sharkey

     

  • The following planners and managers have relevant financial relationships with ineligible companies:

    Name of Planner or Manager

    Reported Financial Relationship

    Pedro Genta, MD (Physician Planner)

     Contracted Research: Biologix, Fisher & Paykel Healthcare, ResMed Foundation.

     

  • Disclosure of Unlabeled Use:

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global does not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

  •  

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Commercial Support Statement

    This activity is supported by an educational grant from Philips Respironics, Inc.

  • Policy on Privacy and Confidentiality

    Global protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Global and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

    Global and Dane Garvin Ltd. maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

  • Copyright

    Copyright© Dane Garvin Ltd. All Rights Reserved. Permission for use granted to accreditation providers.

  • Web interface provided by Dane Garvin Ltd.

     

Contact Us